Published Date: 02 Mar 2023
When adults with cancer take many medications, including blood pressure medications, supplements, or over-the-counter medications such as immunosuppressants, more toxic antibiotics may occur and may lead to the need to avoid the cancer.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Scientists call into question safety of potential new anticancer treatment
2.
Alternative breast imaging techniques beyond mammography.
3.
Skinny melanoma incidence is associated with vitamin D deficiency.
4.
Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer
5.
The lack of psychiatrists may be addressed by community workers.
1.
The Science Behind Imatinib: How It Targets Cancer Cells
2.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
3.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
4.
Exploring The Causes and Consequences of Low Transferrin Saturation
5.
What is Red Cell Distribution Width and Why Should You Care?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation